Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia
Status: Enrolling
Updated:  6/14/2016
St. Francis Hospital
mi
from
Greenville, SC
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia
Status: Enrolling
Updated: 6/14/2016
St. Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
Phase II Study of Intensive "TOTAL THERAPY" for Untreated or Minimally Treated Patients With Multiple Myeloma
Status: Enrolling
Updated:  6/16/2016
University of Arkansas for Medical Sciences/MIRT
mi
from
Little Rock, AR
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
Phase II Study of Intensive "TOTAL THERAPY" for Untreated or Minimally Treated Patients With Multiple Myeloma
Status: Enrolling
Updated: 6/16/2016
University of Arkansas for Medical Sciences/MIRT
mi
from
Little Rock, AR
Click here to add this to my saved trials
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
Phase I/II Trial of Combination of Lenalidomide (Revlimid, LEN) and Autologous Mature Dendritic Cells Pulsed With α-galactosyl Ceramide (α-GalCer; KRN7000) in Myeloma
Status: Enrolling
Updated:  6/20/2016
Yale University School of Medicine
mi
from
New Haven, CT
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
Phase I/II Trial of Combination of Lenalidomide (Revlimid, LEN) and Autologous Mature Dendritic Cells Pulsed With α-galactosyl Ceramide (α-GalCer; KRN7000) in Myeloma
Status: Enrolling
Updated: 6/20/2016
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
Status: Enrolling
Updated:  6/21/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
Status: Enrolling
Updated: 6/21/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
A Combination of Imatinib or Nilotinib Together With Pegylated Interferon-α2b in Chronic-Phase Chronic Myeloid Leukemia: A Phase II Pilot Study Targeting Both the Primitive and Differentiated CML Progenitor Populations
Status: Enrolling
Updated:  6/23/2016
Universtiy of Michigan
mi
from
Ann Arbor, MI
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
A Combination of Imatinib or Nilotinib Together With Pegylated Interferon-α2b in Chronic-Phase Chronic Myeloid Leukemia: A Phase II Pilot Study Targeting Both the Primitive and Differentiated CML Progenitor Populations
Status: Enrolling
Updated: 6/23/2016
Universtiy of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY
Status: Enrolling
Updated:  6/27/2016
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY
Status: Enrolling
Updated: 6/27/2016
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Click here to add this to my saved trials
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY
Status: Enrolling
Updated:  6/27/2016
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY
Status: Enrolling
Updated: 6/27/2016
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY
Status: Enrolling
Updated:  6/27/2016
St. Joseph's Hospital and Medical Center
mi
from
Paterson, NJ
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY
Status: Enrolling
Updated: 6/27/2016
St. Joseph's Hospital and Medical Center
mi
from
Paterson, NJ
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Beebe Medical Center
mi
from
Lewes, DE
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
St. Francis Hospital
mi
from
Wilmington, DE
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
St. Francis Hospital
mi
from
Wilmington, DE
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Union Hospital Cancer Center at Union Hospital
mi
from
Elkton MD, MD
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Union Hospital Cancer Center at Union Hospital
mi
from
Elkton MD, MD
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Siteman Cancer Center at Barnes-Jewish Hospital
mi
from
St Louis, MO
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Siteman Cancer Center at Barnes-Jewish Hospital
mi
from
St Louis, MO
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees
mi
from
Voorhees, NJ
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated:  6/30/2016
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation
Status: Enrolling
Updated: 6/30/2016
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
A Phase I Study of Bortezomib (VELCADE) in Combination With Pralatrexate in Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/5/2016
Stanford University School of Medicine
mi
from
Stanford, CA
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
A Phase I Study of Bortezomib (VELCADE) in Combination With Pralatrexate in Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/5/2016
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated:  7/6/2016
Clinical Research Facility
mi
from
Decatur, GA
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated: 7/6/2016
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated:  7/6/2016
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated: 7/6/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated:  7/6/2016
Clinical Research Facility
mi
from
Fairfax, VA
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated: 7/6/2016
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated:  7/6/2016
Clinical Research Facility
mi
from
Milwaukee, WI
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated: 7/6/2016
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated:  7/6/2016
Investigational Site Number 032001
mi
from
Capital Federal,
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated: 7/6/2016
Investigational Site Number 032001
mi
from
Capital Federal,
Click here to add this to my saved trials
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated:  7/6/2016
Clinical Research Facility
mi
from
Irvine, CA
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated: 7/6/2016
Clinical Research Facility
mi
from
Irvine, CA
Click here to add this to my saved trials
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Status: Enrolling
Updated:  7/11/2016
Pacific Cancer Medical Center
mi
from
Anaheim, CA
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Status: Enrolling
Updated: 7/11/2016
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Status: Enrolling
Updated:  7/11/2016
Cancer Center of Central Connecticut
mi
from
Southington, CT
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Status: Enrolling
Updated: 7/11/2016
Cancer Center of Central Connecticut
mi
from
Southington, CT
Click here to add this to my saved trials
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Status: Enrolling
Updated:  7/11/2016
St. Agnes Healthcare, Site #185
mi
from
Baltimore, MD
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Status: Enrolling
Updated: 7/11/2016
St. Agnes Healthcare, Site #185
mi
from
Baltimore, MD
Click here to add this to my saved trials
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Status: Enrolling
Updated:  7/11/2016
Promedica Hematology & Oncology Assoicates
mi
from
Sylvania, OH
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Status: Enrolling
Updated: 7/11/2016
Promedica Hematology & Oncology Assoicates
mi
from
Sylvania, OH
Click here to add this to my saved trials
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Status: Enrolling
Updated:  7/11/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Status: Enrolling
Updated: 7/11/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Status: Enrolling
Updated:  7/11/2016
Local Institution
mi
from
Creteil Cedex,
This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Status: Enrolling
Updated: 7/11/2016
Local Institution
mi
from
Creteil Cedex,
Click here to add this to my saved trials
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated With Interleukin-2: A CALGB Leukemia Tissue Bank Project
Status: Enrolling
Updated:  7/12/2016
Kinston Medical Specialists
mi
from
Kinston, NC
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated With Interleukin-2: A CALGB Leukemia Tissue Bank Project
Status: Enrolling
Updated: 7/12/2016
Kinston Medical Specialists
mi
from
Kinston, NC
Click here to add this to my saved trials
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated With Interleukin-2: A CALGB Leukemia Tissue Bank Project
Status: Enrolling
Updated:  7/12/2016
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated With Interleukin-2: A CALGB Leukemia Tissue Bank Project
Status: Enrolling
Updated: 7/12/2016
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease
Status: Enrolling
Updated:  7/12/2016
U. Miami - Bascom Palmer Eye Institute
mi
from
Plantation, FL
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease
Status: Enrolling
Updated: 7/12/2016
U. Miami - Bascom Palmer Eye Institute
mi
from
Plantation, FL
Click here to add this to my saved trials
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease
Status: Enrolling
Updated:  7/12/2016
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease
Status: Enrolling
Updated: 7/12/2016
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated:  7/12/2016
CCOP - Christiana Care Health Services
mi
from
Wilmington, DE
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated: 7/12/2016
CCOP - Christiana Care Health Services
mi
from
Wilmington, DE
Click here to add this to my saved trials
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated:  7/12/2016
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated: 7/12/2016
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated:  7/12/2016
North Shore University Hospital
mi
from
Manhasset, NY
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated: 7/12/2016
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated:  7/12/2016
The New York Presbyterian Hospital - Cornell Campus
mi
from
New York, NY
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated: 7/12/2016
The New York Presbyterian Hospital - Cornell Campus
mi
from
New York, NY
Click here to add this to my saved trials
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated:  7/12/2016
CCOP - Southeast Cancer Control Consortium
mi
from
Winston-Salem, NC
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia
Status: Enrolling
Updated: 7/12/2016
CCOP - Southeast Cancer Control Consortium
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
Howard University Cancer Center
mi
from
Washington,
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
Howard University Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials